(Adnkronos) - “Ottenuta l’approvazione della Commissione Europea per il trattamento di donne con questo tipo di tumore mammario ormonosensibile, e un rischio da moderato ad alto di recidive. Incluse le donne senza metastasi ai linfonodi ascellari, in cui lo studio Natalee ha dimostrato una riduzione del 34%. La terapia consiste in due compresse al giorno da assumer per tre anni in aggiunta al classico trattamento ormonale”.
Category
🗞
NewsTranscript
00:00The treatment with Ribociclib is indicated, based on this new EMA approval, in women with early mammary tumor that is of the hormonal-sensitive type, that is, with positive and negative hormonal receptors to HER2, as it is said in Anglo-Saxon terms, HR positive, HER2 negative.
00:23Obviously, these women must have a risk ranging from moderate to high, including women without mitastasis and axillary lymph nodes.
00:32The treatment consists of the absorption of two Ribociclib compresses in addition to the classic hormonal-therapeutic treatment, that is, the hormonal compress that has become extremely familiar to all women in this therapeutic setting.
00:47The addition of the two Ribociclib compresses occurs in the first three years of hormonal treatment.
00:52This therapy has proven to be able to reduce the risk of disease recidivism even over time, based on the latest analysis presented just over a month ago at ESMO, the European Congress of Oncology, of about 29% in the entire population of patients.
01:10For years we have believed that the hormonal-sensitive tumor was a tumor with good prognosis.
01:15In reality it is, it is not particularly aggressive.
01:18But what is the problem?
01:20That recidivism is distributed over a very, very long time frame.
01:25Today we know that they can occur even at a distance of 20 or 30 years.
01:30Therefore, there is a concrete clinical dream to reduce this risk of recidivism,
01:35also because recidivism, which is often represented by metastasis in other parts of the body,
01:41that is, tumor formations that colonize different organs from the starting one, such as the breast,
01:48in such clinical situations are virtually incurable, if not in a minority of cases.
01:55Therefore, it is important to reduce recidivism to increase the definitive healing rates.
02:00The study, carried out at the age of 4, has shown that this therapy with ribocitlib,
02:04performed with the absorption of two compresses a day for three years in addition to the standard hormonal therapy,
02:12further reduces the risk, compared to all other treatments, of about 29%.
02:18This reduction appears even more marked in some populations of patients
02:23who could not previously benefit from these additional therapies,
02:26such as those without metastasis of the axillary lymph nodes,
02:30where even the reduction reaches 34%.
02:34So it is a further step forward towards our final goal,
02:39which we will soon reach, which is a 0% risk of recidivism,
02:44which will obviously be equivalent to 100% healing.